The sleep technology company is shifting its focus toward predictive AI and regulated health, fueled by a new investment round led by Tether Investments.

Key takeaways:

Eight Sleep secured a new strategic investment valuing the company at $1.5 billion to fund its expansion into predictive, artificial intelligence-driven health.
The company is advancing clinical and regulatory pathways in the US, including FDA filings for sleep apnea detection and mitigation.
Capital will be used to scale R&D for predictive models, expand clinical trials, and grow global commercial partnerships.

Eight Sleep announced a new strategic funding round led by Tether Investments, valuing the sleep technology company at $1.5 billion. The investment will fund the company’s expansion from sleep optimization into predictive, artificial intelligence (AI)-driven health.

As part of this shift, Eight Sleep is advancing clinical and regulatory work in the US, which includes Food and Drug Administration (FDA) filings for sleep apnea detection and mitigation. If cleared by the FDA, the Eight Sleep Pod would transition from a wellness product into a regulated health platform designed to screen, detect, and intervene at a population scale passively each night.

“Sleep was just the beginning,” says Matteo Franceschetti, co-founder and chief executive officer of Eight Sleep, in a release. “We’ve built the most advanced AI-powered health sensing system in the world—one that learns your body better every night and acts on that knowledge. This investment gives us the resources to take that intelligence beyond the bedroom and into every dimension of personal health. What we’re building doesn’t exist yet—a system that understands your body better each night and acts on that knowledge. Our goal is to build the defining health technology company of this generation.”

The company is developing a predictive AI agent that anticipates how a user’s night will unfold to intervene before sleep disruption occurs. The system simulates various scenarios—such as a warm room, late exercise, a large meal, or elevated stress—and optimizes the sleep environment before the user gets into bed. This builds upon the Pod’s current reactive capabilities, which track biometrics like sleep stages, heart rate, and heart rate variability to automatically adjust temperature and elevation.

Eight Sleep’s models are trained on more than one billion hours of real-world sleep data from users in over 35 countries. Early pilots of daytime AI-driven guidance resulted in measurable behavior changes, with nearly half of participants adjusting activity timing, caffeine intake, or sleep schedules based on automated insights.

The funding round follows a year of growth for the company. In 2025, Eight Sleep launched three new products—Pod 5, Pod Pillow Cover, and Thermal Blanket—and achieved free cash flow positivity. The company also conducted clinical validation, with two peer-reviewed studies showing the Pod reduces menopausal hot flashes by 56% and restores the body’s natural circadian temperature rhythm during sleep to improve cardiovascular recovery markers.

“We believe advanced personalized AI is the perfect pathway to understand and expand human potential,” says Paolo Ardoino, CEO of Tether, in a release. “Eight Sleep has the potential to define the future of health tech by building intelligence that learns, scales, and evolves directly with humankind, turning advanced AI into practical, everyday insights and enhancements about core human biology. By helping people better understand sleep, recovery, and long-term health, Eight Sleep is laying the groundwork for a new standard in longevity-focused technology that is truly personalized, can function in any condition, directly on-device, resilient, and aligned with how people live. The age of human-first health intelligence has started.”

The new capital will be deployed across three main areas: scaling R&D to accelerate predictive model development, expanding clinical trials and regulatory pathways, and deepening global commercial partnerships in priority markets.